Leerink Partnrs Comments on AbbVie’s Q3 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) – Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for AbbVie in a research report issued on Thursday, July 31st. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $3.34 per share for the quarter, up from their previous forecast of $3.18. The consensus estimate for AbbVie’s current full-year earnings is $12.31 per share. Leerink Partnrs also issued estimates for AbbVie’s Q4 2025 earnings at $3.27 EPS, FY2026 earnings at $14.27 EPS, FY2027 earnings at $16.01 EPS, FY2028 earnings at $18.15 EPS and FY2029 earnings at $19.59 EPS.

ABBV has been the topic of several other reports. Cantor Fitzgerald began coverage on AbbVie in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $210.00 price objective on the stock. Raymond James Financial boosted their price target on AbbVie from $227.00 to $236.00 and gave the stock an “outperform” rating in a research report on Friday. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. The Goldman Sachs Group reissued a “neutral” rating and issued a $194.00 price target on shares of AbbVie in a research report on Tuesday, April 8th. Finally, Citigroup boosted their price target on AbbVie to $205.00 and gave the stock a “hold” rating in a research report on Wednesday, June 11th. Eight investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and a consensus price target of $212.81.

AbbVie Stock Up 3.3%

Shares of NYSE:ABBV opened at $195.17 on Monday. The stock’s 50-day moving average is $188.33 and its 200 day moving average is $190.42. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64. The company has a market cap of $344.75 billion, a PE ratio of 92.94, a P/E/G ratio of 1.27 and a beta of 0.50. AbbVie has a 1 year low of $163.81 and a 1 year high of $218.66.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.24 by ($0.27). AbbVie had a net margin of 6.45% and a return on equity of 518.10%. The business had revenue of $15.42 billion for the quarter, compared to analysts’ expectations of $14.93 billion. During the same quarter in the prior year, the firm earned $2.65 EPS. The firm’s revenue for the quarter was up 6.6% on a year-over-year basis.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be issued a $1.64 dividend. The ex-dividend date of this dividend is Tuesday, July 15th. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.4%. AbbVie’s dividend payout ratio (DPR) is presently 312.38%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ABBV. Brighton Jones LLC increased its position in shares of AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC boosted its stake in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Grantham Mayo Van Otterloo & Co. LLC boosted its stake in AbbVie by 17.1% in the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 7,233 shares of the company’s stock valued at $1,285,000 after acquiring an additional 1,054 shares in the last quarter. Perennial Investment Advisors LLC boosted its stake in AbbVie by 15.8% in the fourth quarter. Perennial Investment Advisors LLC now owns 3,882 shares of the company’s stock valued at $690,000 after acquiring an additional 530 shares in the last quarter. Finally, Darden Wealth Group Inc boosted its stake in AbbVie by 2.1% in the fourth quarter. Darden Wealth Group Inc now owns 4,832 shares of the company’s stock valued at $859,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.